Parkinson Disease
Conditions
Keywords
Deep Brain Stimulation, DBS, PD
Brief summary
The purpose of this study is to obtain clinical outcome data on safety and effectiveness of the directSTIM DBS system when used on-label, according to the instructions for use. All participants will undergo bilateral implant in the subthalamic nucleus (STN) and data collected in common practice will be recorded during six months post-implant and analyzed.
Detailed description
directSTIM DBS Therapy for Movement Disorders is indicated for patients with disabling tremor or symptoms of Parkinson's disease. Subjects selected to participate in the study will be Parkinson's Disease (PD) patients who are eligible for bilateral DBS for STN therapy and meet the inclusion criteria and none of the exclusion criteria. Primary safety and effectiveness endpoints data will be collected through 6 months of follow-up. The values used for comparison are derived from a review of literature spanning from 2001 to 2019. After completing the 6 month follow-up, subject will exit the study, and continue to be followed by their physician per usual care.
Interventions
PROCEDUREDeep Brain Stimulation
Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
Sponsors
Aleva Neurotherapeutics SA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Established diagnosis of idiopathic Parkinson's Disease for 4 years or more according to the United Kingdom Parkinson's disease Brain Bank criteria, with disabling motor complications despite optimal medical treatment. * Patient is eligible for bilateral DBS for STN therapy according to center's routine criteria and according to the directSTIM DBS system Indications for Use statement. * Patient who is willing to provide a written informed consent. * Patient complies with the study follow-up, in particular the follow-up visits, and other study requirements.
Exclusion criteria
* Patient is not eligible for DBS per center criteria. * Patient has a cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to complete study assessments, such as: * Active major psychiatric disorder. * Dementia (MoCa Dementia Rating Scale score \<26 or otherwise not capable of discernment). * Presence of an electrical or electromagnetic implant (e.g. cochlear implant, pacemaker). * Previous surgery for the treatment of Parkinson's disease. * Previous brain ablation procedure. * Epilepsy. * Coagulopathies. * Abuse of drugs or alcohol. * Patient is participating in another clinical study that would confound data analysis. * Patient is pregnant or nursing. As for other DBS systems, the effects of the device on an unborn child are not established.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in UPDRS III score without medication | 6 months compared to baseline | Part 3 of the Unified Parkinson's Disease Rating Scale (UPDRS III), is a series of questions evaluated by the clinician in presence of the patient, focusing on motor symptoms of PD. Score is expressed on a scale of 0 to 108. This score is evaluated at baseline and 6 months post-implant without any anti-Parkinson medication taken. A decrease at 6 months compared to baseline indicates an improvement. The average difference of scores between the two time points is calculated for the whole study subject population. This value is to be compared to the results of a meta-analysis performed on data extracted during a literature search. |
| Materiovigilance | 6 months | Summary statistics on the occurrence of the following categories of adverse events (AEs): * Device-related AEs * Procedure-related AEs * Stimulation-related AEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Therapeutic Window (TW) | 3 months | The therapeutic window is the difference of electrical current values between the stimulation settings that provide maximum alleviation of motor symptoms and the settings for which the first stimulation-induced side effect appears (e.g., eye deviation, muscle contraction, speech impairment). The wider this window, the more flexibility is offered to the patient for stimulation without causing side-effects. |
| UPDRS | 6 months | Other parts (I, II and IV) of the Unified Parkinson's Disease Scale are evaluated at baseline and 6 months post-implant. Part I is a series of 4 questions assessing Mentation, Behavior and Mood. Patient's score is expressed on a scale of 0 to 16. Part II is a series of 13 questions assessing Quality of Life in daily activities. Patient's score is expressed on a scale of 0 to 52. Part IV is a series of 10 questions assessing Complications of Therapy. Patient's score is expressed on a scale of 0 to 23. A decrease at 6 months compared to baseline indicates an improvement. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in PDQ-39 score | 6 months | Parkinson's Disease Questionnaire-39, a patient-filled questionnaire focusing on quality of life, is completed by study subjects at baseline and 6 months post-implant. Score is expressed on a scale of 0 to 100. A decrease at 6 months compared to baseline indicates an improvement. The average difference of scores between the two time points is calculated for the whole study subject population. |
| Change in dopaminergic medication | 6 months | The Levodopa equivalent daily dose (LEDD) is expressed as Levodopa equivalent mg/day and measured through the whole study duration. Evolution of this value is followed and the difference between baseline and 6 months post-implant timepoints is to be compared to the results of a meta-analysis performed on data extracted during a literature search. |
Countries
Germany
Contacts
Primary ContactAlain Dransart
Backup ContactMatthias Möhlmann, MD
Outcome results
None listed